Skip to main content
Premium Trial:

Request an Annual Quote

GENOME express Closes $11M in Second Financing Round

NEW YORK, Dec. 10 - French genomics-tool company GENOME express has raised 12.4 million euros, or roughly $11 million, in a second round of financing, the company said on Monday.

 

It said it plans to use the cash to leverage its high throughput DNA sequencing and related products, including DNA libraries, bioinformatics, and data qualification, as well as to discover new therapeutic targets in microbiology and the central nervous system.

 

"We plan to grow GENOME express in international markets both organically and by acquisition," Yves Laurent, CEO of GENOME express, said in a statement. "Over 2002, we will develop our ability to generate intellectual property, offer high added value to our customers and create mutually beneficial partnerships."

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.